<DOC>
	<DOC>NCT02402686</DOC>
	<brief_summary>The aim of this non-interventional study in Hungarian patients is to gather real life data about the efficacy and safety of tocilizumab subcutaneous (SC) monotherapy in rheumatoid arthritis and to assess data about pattern of usage of tocilizumab monotherapy in rheumatoid arthritis (RA) disease management.</brief_summary>
	<brief_title>Non-Interventional Study of Tocilizumab Subcutaneous Monotherapy in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>At least 18 years of age Moderate to severe RA according to 2010 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) joint criteria Treatment with tocilizumab SC monotherapy for up to 8 weeks prior to enrollment, under the prescriptive authority of a physician who has made the decision to commence tocilizumab in accordance with the local label Methotrexate intolerance, or inadequate response to prior diseasemodifying antirheumatic drugs (DMARDs) and tumor necrosis factor (TNF) inhibitors where continued methotrexate treatment was deemed inappropriate Treatment with tocilizumab more than 8 weeks prior to enrollment Failure to meet local tocilizumab label indication criteria Treatment with any investigational agent within 4 weeks of beginning tocilizumab SC monotherapy Last methotrexate dose within 1 week of beginning tocilizumab SC monotherapy History of any other autoimmune or joint inflammatory disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>